Importantly, in patients who had preserved ejection fraction, both (Anker et al., 2021) [17] and DELIVER (Lassen et al., 2024) [25] confirmed that SGLT2 inhibitors may contribute to a decrease in hospitalizations due to HF, even in this historically treatment-resistant group. The gene discussed is SLC5A2; the disease is hydrops fetalis.